A citation-based method for searching scientific literature

Malak Abedalthagafi, Wenya Linda Bi, Ayal A Aizer, Parker H Merrill, Ryan Brewster, Pankaj K Agarwalla, Marc L Listewnik, Dora Dias-Santagata, Aaron R Thorner, Paul Van Hummelen, Priscilla K Brastianos, David A Reardon, Patrick Y Wen, Ossama Al-Mefty, Shakti H Ramkissoon, Rebecca D Folkerth, Keith L Ligon, Azra H Ligon, Brian M Alexander, Ian F Dunn, Rameen Beroukhim, Sandro Santagata. Neuro Oncol 2016
Times Cited: 148







List of co-cited articles
901 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Victoria E Clark, E Zeynep Erson-Omay, Akdes Serin, Jun Yin, Justin Cotney, Koray Ozduman, Timuçin Avşar, Jie Li, Phillip B Murray, Octavian Henegariu,[...]. Science 2013
486
85

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
Priscilla K Brastianos, Peleg M Horowitz, Sandro Santagata, Robert T Jones, Aaron McKenna, Gad Getz, Keith L Ligon, Emanuele Palescandolo, Paul Van Hummelen, Matthew D Ducar,[...]. Nat Genet 2013
377
68

DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
Felix Sahm, Daniel Schrimpf, Damian Stichel, David T W Jones, Thomas Hielscher, Sebastian Schefzyk, Konstantin Okonechnikov, Christian Koelsche, David E Reuss, David Capper,[...]. Lancet Oncol 2017
330
55

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
47

Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas.
Victoria E Clark, Akdes Serin Harmancı, Hanwen Bai, Mark W Youngblood, Tong Ihn Lee, Jacob F Baranoski, A Gulhan Ercan-Sencicek, Brian J Abraham, Abraham S Weintraub, Denes Hnisz,[...]. Nat Genet 2016
171
45

TERT Promoter Mutations and Risk of Recurrence in Meningioma.
Felix Sahm, Daniel Schrimpf, Adriana Olar, Christian Koelsche, David Reuss, Juliane Bissel, Annekathrin Kratz, David Capper, Sebastian Schefzyk, Thomas Hielscher,[...]. J Natl Cancer Inst 2015
188
45

Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
David E Reuss, Rosario M Piro, David T W Jones, Matthias Simon, Ralf Ketter, Marcel Kool, Albert Becker, Felix Sahm, Stefan Pusch, Jochen Meyer,[...]. Acta Neuropathol 2013
146
37

BAP1 mutations in high-grade meningioma: implications for patient care.
Ganesh M Shankar, Sandro Santagata. Neuro Oncol 2017
80
42

High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.
Stéphane Goutagny, Jean C Nault, Maxime Mallet, Dominique Henin, Jessica Z Rossi, Michel Kalamarides. Brain Pathol 2014
158
32

Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.
Ganesh M Shankar, Malak Abedalthagafi, Rachael A Vaubel, Parker H Merrill, Naema Nayyar, Corey M Gill, Ryan Brewster, Wenya Linda Bi, Pankaj K Agarwalla, Aaron R Thorner,[...]. Neuro Oncol 2017
67
44

Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.
M H Ruttledge, J Sarrazin, S Rangaratnam, C M Phelan, E Twist, P Merel, O Delattre, G Thomas, M Nordenskjöld, V P Collins. Nat Genet 1994
443
29

Genomic landscape of high-grade meningiomas.
Wenya Linda Bi, Noah F Greenwald, Malak Abedalthagafi, Jeremiah Wala, Will J Gibson, Pankaj K Agarwalla, Peleg Horowitz, Steven E Schumacher, Ekaterina Esaulova, Yu Mei,[...]. NPJ Genom Med 2017
85
34

SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
Julien Boetto, Franck Bielle, Marc Sanson, Matthieu Peyre, Michel Kalamarides. Neuro Oncol 2017
51
52

Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas.
Miriam J Smith, James O'Sullivan, Sanjeev S Bhaskar, Kristen D Hadfield, Gemma Poke, John Caird, Saba Sharif, Diana Eccles, David Fitzpatrick, Daniel Rawluk,[...]. Nat Genet 2013
154
24

EANO guidelines for the diagnosis and treatment of meningiomas.
Roland Goldbrunner, Giuseppe Minniti, Matthias Preusser, Michael D Jenkinson, Kita Sallabanda, Emmanuel Houdart, Andreas von Deimling, Pantelis Stavrinou, Florence Lefranc, Morten Lund-Johansen,[...]. Lancet Oncol 2016
377
23

Integrated genomic analyses of de novo pathways underlying atypical meningiomas.
Akdes Serin Harmancı, Mark W Youngblood, Victoria E Clark, Süleyman Coşkun, Octavian Henegariu, Daniel Duran, E Zeynep Erson-Omay, Leon D Kaulen, Tong Ihn Lee, Brian J Abraham,[...]. Nat Commun 2017
91
24

DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management.
Farshad Nassiri, Yasin Mamatjan, Suganth Suppiah, Jetan H Badhiwala, Sheila Mansouri, Shirin Karimi, Olli Saarela, Laila Poisson, Irina Gepfner-Tuma, Jens Schittenhelm,[...]. Neuro Oncol 2019
83
26

Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.
Leland Rogers, Igor Barani, Marc Chamberlain, Thomas J Kaley, Michael McDermott, Jeffrey Raizer, David Schiff, Damien C Weber, Patrick Y Wen, Michael A Vogelbaum. J Neurosurg 2015
304
21

Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Thomas J Kaley, Patrick Wen, David Schiff, Keith Ligon, Sam Haidar, Sasan Karimi, Andrew B Lassman, Craig P Nolan, Lisa M DeAngelis, Igor Gavrilovic,[...]. Neuro Oncol 2015
143
21

Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Ümmügülsüm Yesilöz, Elmar Kirches, Christian Hartmann, Johannes Scholz, Siegfried Kropf, Felix Sahm, Makoto Nakamura, Christian Mawrin. Neuro Oncol 2017
47
44

Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma.
Adriana Olar, Khalida M Wani, Charmaine D Wilson, Gelareh Zadeh, Franco DeMonte, David T W Jones, Stefan M Pfister, Erik P Sulman, Kenneth D Aldape. Acta Neuropathol 2017
71
29


Genetic landscape of meningioma.
Sayaka Yuzawa, Hiroshi Nishihara, Shinya Tanaka. Brain Tumor Pathol 2016
66
28

Advances in meningioma genetics: novel therapeutic opportunities.
Matthias Preusser, Priscilla K Brastianos, Christian Mawrin. Nat Rev Neurol 2018
78
24

Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas.
Miriam J Smith, Andrew J Wallace, Chris Bennett, Martin Hasselblatt, Ewelina Elert-Dobkowska, Linton T Evans, William F Hickey, Jack van Hoff, David Bauer, Amy Lee,[...]. J Pathol 2014
77
22

Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.
Yongli Ji, Cathryn Rankin, Steven Grunberg, Andy E Sherrod, Jamshid Ahmadi, Jeannette J Townsend, Lynn G Feun, Ruth K Fredericks, Christy A Russell, Fairooz F Kabbinavar,[...]. J Clin Oncol 2015
65
26

Pathological classification and molecular genetics of meningiomas.
Christian Mawrin, Arie Perry. J Neurooncol 2010
266
17

Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas.
Mark W Youngblood, Daniel Duran, Julio D Montejo, Chang Li, Sacit Bulent Omay, Koray Özduman, Amar H Sheth, Amy Y Zhao, Evgeniya Tyrtova, Danielle F Miyagishima,[...]. J Neurosurg 2019
40
42

AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry.
Felix Sahm, Juliane Bissel, Christian Koelsche, Leonille Schweizer, David Capper, David Reuss, Katja Böhmer, Ulrike Lass, Tanja Göck, Katrin Kalis,[...]. Acta Neuropathol 2013
68
23

NF2 status of meningiomas is associated with tumour localization and histology.
J Kros, K de Greve, A van Tilborg, W Hop, H Pieterman, C Avezaat, R Lekanne Dit Deprez, E Zwarthoff. J Pathol 2001
78
20

Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas.
Matthew R Strickland, Corey M Gill, Naema Nayyar, Megan R D'Andrea, Christian Thiede, Tareq A Juratli, Gabriele Schackert, Darrell R Borger, Sandro Santagata, Matthew P Frosch,[...]. J Neurosurg 2017
32
50

Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status.
Stéphane Goutagny, Hong Wei Yang, Jessica Zucman-Rossi, Jennifer Chan, Jonathan M Dreyfuss, Peter J Park, Peter M Black, Marco Giovannini, Rona S Carroll, Michel Kalamarides. Clin Cancer Res 2010
69
21

Epidemiology and etiology of meningioma.
Joseph Wiemels, Margaret Wrensch, Elizabeth B Claus. J Neurooncol 2010
585
15

DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome.
Tareq A Juratli, Devin McCabe, Naema Nayyar, Erik A Williams, Ian M Silverman, Shilpa S Tummala, Alexandria L Fink, Aymen Baig, Maria Martinez-Lage, Martin K Selig,[...]. Acta Neuropathol 2018
40
37

Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
Thomas Graillon, Marc Sanson, Chantal Campello, Ahmed Idbaih, Matthieu Peyre, Hadrien Peyrière, Noémie Basset, Didier Autran, Catherine Roche, Michel Kalamarides,[...]. Clin Cancer Res 2020
39
38

Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes.
M Kalamarides, A O Stemmer-Rachamimov, M Niwa-Kawakita, F Chareyre, E Taranchon, Z-Y Han, C Martinelli, E A Lusis, B Hegedus, D H Gutmann,[...]. Oncogene 2011
93
15

A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
Kent C Shih, Sajeel Chowdhary, Paul Rosenblatt, Alva B Weir, Gregg C Shepard, Jeffrey T Williams, Mythili Shastry, Howard A Burris, John D Hainsworth. J Neurooncol 2016
50
28

Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system.
Sayaka Yuzawa, Hiroshi Nishihara, Shigeru Yamaguchi, Hiromi Mohri, Lei Wang, Taichi Kimura, Masumi Tsuda, Mishie Tanino, Hiroyuki Kobayashi, Shunsuke Terasaka,[...]. Mod Pathol 2016
27
51

Atypical and anaplastic meningiomas treated with bevacizumab.
Lakshmi Nayak, Fabio M Iwamoto, Jeremy D Rudnick, Andrew D Norden, Eudocia Quant Lee, Jan Drappatz, Antonio Omuro, Thomas J Kaley. J Neurooncol 2012
110
14

A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma.
Ayal A Aizer, Malak Abedalthagafi, Wenya Linda Bi, Margaret C Horvath, Nils D Arvold, Ossama Al-Mefty, Eudocia Q Lee, Lakshmi Nayak, Mikael L Rinne, Andrew D Norden,[...]. Neuro Oncol 2016
48
29

Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
J Boström, B Meyer-Puttlitz, M Wolter, B Blaschke, R G Weber, P Lichter, K Ichimura, V P Collins, G Reifenberger. Am J Pathol 2001
179
14

Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363.
Michael Weller, Patrick Roth, Felix Sahm, Isabel Burghardt, Bernhard Schuknecht, Elisabeth J Rushing, Luca Regli, Justin P Lindemann, Andreas von Deimling. J Natl Cancer Inst 2017
28
46

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
Emil Lou, Ashley L Sumrall, Scott Turner, Katherine B Peters, Annick Desjardins, James J Vredenburgh, Roger E McLendon, James E Herndon, Frances McSherry, Julie Norfleet,[...]. J Neurooncol 2012
114
13

Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.
Ziming Du, Malak Abedalthagafi, Ayal A Aizer, Allison R McHenry, Heather H Sun, Mark-Anthony Bray, Omar Viramontes, Revaz Machaidze, Priscilla K Brastianos, David A Reardon,[...]. Oncotarget 2015
87
14

An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures.
Grace Collord, Patrick Tarpey, Natalja Kurbatova, Inigo Martincorena, Sebastian Moran, Manuel Castro, Tibor Nagy, Graham Bignell, Francesco Maura, Matthew D Young,[...]. Sci Rep 2018
25
52

TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
Sabine Spiegl-Kreinecker, Daniela Lötsch, Katharina Neumayer, Lucia Kastler, Johannes Gojo, Christine Pirker, Josef Pichler, Serge Weis, Rajiv Kumar, Gerald Webersinke,[...]. Neuro Oncol 2018
53
24

ARID1A and TERT promoter mutations in dedifferentiated meningioma.
Malak S Abedalthagafi, Wenya Linda Bi, Parker H Merrill, William J Gibson, Matthew F Rose, Ziming Du, Joshua M Francis, Rose Du, Ian F Dunn, Azra H Ligon,[...]. Cancer Genet 2015
56
21

Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma.
R Wellenreuther, J A Kraus, D Lenartz, A G Menon, J Schramm, D N Louis, V Ramesh, J F Gusella, O D Wiestler, A von Deimling. Am J Pathol 1995
218
12

Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.
Thomas Kaley, Igor Barani, Marc Chamberlain, Michael McDermott, Katherine Panageas, Jeffrey Raizer, Leland Rogers, David Schiff, Michael Vogelbaum, Damien Weber,[...]. Neuro Oncol 2014
125
12

The ROAM/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial.
Michael D Jenkinson, Mohsen Javadpour, Brian J Haylock, Bridget Young, Helen Gillard, Jacqui Vinten, Helen Bulbeck, Kumar Das, Michael Farrell, Seamus Looby,[...]. Trials 2015
107
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.